Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
12.12
+0.44 (3.77%)
Apr 28, 2025, 4:08 PM HKT
HKG:2315 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 403.85 | 417.66 | 626.62 | 466.45 | 750.04 |
Short-Term Investments | - | 7.89 | 9.15 | 106.98 | 207.37 |
Trading Asset Securities | - | 8.49 | 8.2 | - | - |
Cash & Short-Term Investments | 403.85 | 434.04 | 643.97 | 573.42 | 957.41 |
Cash Growth | -6.96% | -32.60% | 12.30% | -40.11% | - |
Accounts Receivable | 229.61 | 142.38 | 107.68 | 103.09 | 67.23 |
Other Receivables | - | 6.04 | 4.17 | 14.96 | 14.7 |
Receivables | 229.61 | 148.43 | 111.85 | 118.05 | 81.93 |
Inventory | 3.89 | 9.9 | 23.73 | 21.65 | 10.21 |
Other Current Assets | 179.19 | 130.69 | 139.74 | 161.11 | 98.08 |
Total Current Assets | 816.54 | 723.05 | 919.3 | 874.24 | 1,148 |
Property, Plant & Equipment | 1,349 | 1,451 | 1,599 | 1,391 | 1,136 |
Long-Term Investments | 159.04 | 241.24 | 250.81 | 9.69 | 10.09 |
Other Intangible Assets | 20.67 | 28.13 | 30.65 | 6.06 | 2.43 |
Long-Term Deferred Tax Assets | 0.96 | - | - | - | - |
Other Long-Term Assets | 68.63 | 6.16 | - | 21.86 | 30.77 |
Total Assets | 2,415 | 2,449 | 2,800 | 2,303 | 2,327 |
Accounts Payable | 115.48 | 175.23 | 146.19 | 102.44 | 87.6 |
Accrued Expenses | - | 27.89 | 51.62 | 53.66 | 27.41 |
Current Portion of Long-Term Debt | 208.14 | 176.84 | 126.67 | - | - |
Current Portion of Leases | 17.86 | 26.36 | 44.94 | 26.9 | 14.11 |
Current Income Taxes Payable | 4.01 | 4.51 | 4.2 | 5.02 | 1.42 |
Current Unearned Revenue | 102.19 | 69.22 | 56.38 | 61.58 | 47.51 |
Other Current Liabilities | 87.24 | 97.56 | 176.06 | 196.96 | 150.42 |
Total Current Liabilities | 534.91 | 577.62 | 606.05 | 446.56 | 328.47 |
Long-Term Debt | 193.84 | 173.91 | 52.17 | - | - |
Long-Term Leases | 150.45 | 167.01 | 191.51 | 62.9 | 66.81 |
Long-Term Unearned Revenue | 84.9 | 87.07 | 89.93 | 92.8 | 90.12 |
Long-Term Deferred Tax Liabilities | - | 1.9 | - | - | - |
Other Long-Term Liabilities | 612.62 | 651.48 | 709.36 | 448.55 | 382.88 |
Total Liabilities | 1,577 | 1,659 | 1,649 | 1,051 | 868.28 |
Common Stock | 399.4 | 399.4 | 399.4 | 374.93 | 360 |
Additional Paid-In Capital | - | 1,992 | 1,992 | 1,516 | 1,219 |
Retained Earnings | - | -1,787 | -1,404 | -802.32 | -256.75 |
Treasury Stock | - | -27.18 | -18.99 | - | - |
Comprehensive Income & Other | 434.66 | 209.09 | 178.32 | 159.03 | 130.69 |
Total Common Equity | 834.06 | 785.89 | 1,146 | 1,247 | 1,453 |
Minority Interest | 4.55 | 4.55 | 4.55 | 4.76 | 4.83 |
Shareholders' Equity | 838.6 | 790.44 | 1,151 | 1,252 | 1,458 |
Total Liabilities & Equity | 2,415 | 2,449 | 2,800 | 2,303 | 2,327 |
Total Debt | 570.28 | 544.11 | 415.28 | 89.8 | 80.92 |
Net Cash (Debt) | -166.43 | -110.07 | 228.69 | 483.62 | 876.5 |
Net Cash Growth | - | - | -52.71% | -44.82% | - |
Net Cash Per Share | -0.42 | -0.28 | 0.60 | 1.33 | 6.79 |
Filing Date Shares Outstanding | 399.4 | 399.4 | 399.4 | 396.69 | 129.06 |
Total Common Shares Outstanding | 399.4 | 399.4 | 399.4 | 374.93 | 129.06 |
Working Capital | 281.62 | 145.43 | 313.25 | 427.68 | 819.17 |
Book Value Per Share | 2.09 | 1.97 | 2.87 | 3.33 | 11.26 |
Tangible Book Value | 813.39 | 757.76 | 1,116 | 1,241 | 1,451 |
Tangible Book Value Per Share | 2.04 | 1.90 | 2.79 | 3.31 | 11.24 |
Machinery | - | 1,437 | 1,208 | 1,107 | 849.69 |
Construction In Progress | - | 5.19 | 268.29 | 181.96 | 210.83 |
Leasehold Improvements | - | 240.53 | 161.75 | 166.43 | 44.07 |
Updated Sep 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.